文献速递流行病学与生物统计基础与转化研究

COVID-19血清学检测诊断准确性的系统评价与荟萃分析

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis.
PubMed 文献 · BMJ · 2020-07-01

该系统评价纳入40项研究,评估COVID-19血清学检测(ELISA、LFIA、CLIA)的灵敏度和特异度。合并灵敏度ELISA为84.3%、LFIA为66.0%、CLIA为97.8%,特异度96.6%-99.7%。现有证据不支持继续使用即时血清学检测。

要点

  • 即时LFIA合并灵敏度仅66.0%,低于ELISA和CLIA。
  • 症状出现3周后灵敏度(69.9%-98.9%)高于第一周(13.4%-50.3%)。
  • 98%评估存在患者选择高偏倚风险,高质量研究亟待开展。

核心结论

  • 现有证据不支持继续使用即时血清学检测。
  • 亟需更高质量临床研究评估COVID-19血清学检测准确性。

研究设计与样本

  • 系统评价与荟萃分析,检索Medline、bioRxiv和medRxiv(2020年1月1日至4月30日)。
  • 纳入40项研究,进行49项偏倚风险评估(每个评估的人群和方法各一项)。
  • 合并灵敏度和特异度采用随机效应双变量荟萃分析。

主要发现

  • ELISA(测IgG或IgM)合并灵敏度84.3%(95%CI 75.6%至90.9%)。
  • LFIA合并灵敏度66.0%(95%CI 49.3%至79.3%)。
  • CLIA合并灵敏度97.8%(95%CI 46.2%至100%)。
  • 合并特异度范围为96.6%至99.7%。
  • LFIA中商品试剂盒合并灵敏度65.0%(95%CI 49.0%至78.2%)低于非商品试剂盒88.2%(95%CI 83.6%至91.3%)。

关键数值与推荐

  • 症状出现至少3周后灵敏度范围为69.9%至98.9%,第一周内为13.4%至50.3%。
  • 98%(48/49)评估存在患者选择高偏倚风险,73%(36/49)存在检测实施或解释高/不明确偏倚风险。
  • 仅10%(4/40)研究纳入门诊患者,仅两项研究评估即时检测。

临床怎么用

  • 即时血清学检测灵敏度较低,不宜作为COVID-19诊断依据。
  • 结果解读需考虑症状出现时间,3周后灵敏度较高。
  • 需结合病毒培养或RT-PCR参考标准综合判断。

局限性

  • 高偏倚风险普遍,患者选择偏倚突出。
  • 门诊和即时检测研究代表性不足。
  • 所有分析均存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the diagnostic accuracy of serological tests for coronavirus disease-2019 (covid-19). DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, bioRxiv, and medRxiv from 1 January to 30 April 2020, using subject headings or subheadings combined with text words for the concepts of covid-19 and serological tests for covid-19. ELIGIBILITY CRITERIA AND DATA ANALYSIS: Eligible studies measured sensitivity or specificity, or both of a covid-19 serological test compared with a reference standard of viral culture or reverse transcriptase polymerase chain reaction. Studies were excluded with fewer than five participants or samples. Risk of bias was assessed using quality assessment of diagnostic accuracy studies 2 (QUADAS-2). Pooled sensitivity and specificity were estimated using random effects bivariate meta-analyses. MAIN OUTCOME MEASURES: The primary outcome was overall sensitivity and specificity, stratified by method of serological testing (enzyme linked immunosorbent assays (ELISAs), lateral flow immunoassays (LFIAs), or chemiluminescent immunoassays (CLIAs)) and immunoglobulin class (IgG, IgM, or both). Secondary outcomes were stratum specific sensitivity and specificity within subgroups defined by study or participant characteristics, including time since symptom onset. RESULTS: 5016 references were identified and 40 studies included. 49 risk of bias assessments were carried out (one for each population and method evaluated). High risk of patient selection bias was found in 98% (48/49) of assessments and high or unclear risk of bias from performance or interpretation of the serological test in 73% (36/49). Only 10% (4/40) of studies included outpatients. Only two studies evaluated tests at the point of care. For each method of testing, pooled sensitivity and specificity were not associated with the immunoglobulin class measured. The pooled sensitivity of ELISAs measuring IgG or IgM was 84.3% (95% confidence interval 75.6% to 90.9%), of LFIAs was 66.0% (49.3% to 79.3%), and of CLIAs was 97.8% (46.2% to 100%). In all analyses, pooled sensitivity was lower for LFIAs, the potential point-of-care method. Pooled specificities ranged from 96.6% to 99.7%. Of the samples used for estimating specificity, 83% (10 465/12 547) were from populations tested before the epidemic or not suspected of having covid-19. Among LFIAs, pooled sensitivity of commercial kits (65.0%, 49.0% to 78.2%) was lower than that of non-commercial tests (88.2%, 83.6% to 91.3%). Heterogeneity was seen in all analyses. Sensitivity was higher at least three weeks after symptom onset (ranging from 69.9% to 98.9%) compared with within the first week (from 13.4% to 50.3%). CONCLUSION: Higher quality clinical studies assessing the diagnostic accuracy of serological tests for covid-19 are urgently needed. Currently, available evidence does not support the continued use of existing point-of-care serological tests. STUDY REGISTRATION: PROSPERO CRD42020179452.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020. PMID: 32611558. doi:10.1136/bmj.m2516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。